Halozyme Therapeutics Inc at Barclays Global Healthcare Conference Transcript
Good afternoon, everyone. My name is Gena Wang. I am the SMid-Cap biotech analyst from Barclays.
It's my pleasure to introduce our next speaker Laurie Stelzer, Chief Financial Officer, from Halozyme.
Thank you, Gena, and let me grab the clicker. Okay. Good afternoon, everyone. I am delighted to be here today to talk about Halozyme. Halozyme is a unique biotech company. We have a very unique strategy with a 2 pillar structure for growth. I'm going to talk about both those pillars but both pillars, both ENHANZE and PEGPH20 really will drive a great deal of shareholder value.
Before I get started, the forward-looking statements I'll be making today, I direct you to our SEC filings for a full list of risks and uncertainties.
So as I mentioned, we have 2 pillars for growth, 2 engines for growth in the future. On the left-hand side, you'll see our ENHANZE. This is a drug technology platform. In this
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
